Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

Aims Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and improved quality of life when used to treat ID at discharge in patients hospitalized for acute HF with left ventricular ejec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of heart failure 2023-03, Vol.25 (3), p.389-398
Hauptverfasser:	McEwan, Phil, Harrison, Cale, Binnie, Rhona, Lewis, Ruth D., Cohen‐Solal, Alain, Lund, Lars H., Ohlsson, Marcus, Haehling, Stephan, Comin‐Colet, Josep, Pascual‐Figal, Domingo A., Wächter, Sandra, Dorigotti, Fabio, Arellano, Antonio Ramirez, Ponikowski, Piotr, Jankowska, Ewa A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia, Iron-Deficiency - complications Anemia, Iron-Deficiency - drug therapy Anemia, Iron-Deficiency - epidemiology Budget impact Burden of disease Cost-Benefit Analysis Cost‐effectiveness Ferric carboxymaltose Ferric Compounds - therapeutic use Heart failure Heart Failure - complications Heart Failure - drug therapy Heart Failure - epidemiology Hospitalization Humans Iron Deficiencies Iron deficiency Maltose - therapeutic use Medicin och hälsovetenskap Patient Discharge Quality of Life Stroke Volume Ventricular Function, Left
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Iron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and improved quality of life when used to treat ID at discharge in patients hospitalized for acute HF with left ventricular ejection fraction
ISSN:	1388-9842 1879-0844 1879-0844
DOI:	10.1002/ejhf.2788